公司问答丨智翔金泰：GR2102注射液目前处于Ⅰ期临床试验阶段
Chongqing Genrix Biopharmaceutical Chongqing Genrix Biopharmaceutical (SH:688443) Ge Long Hui A P P·2025-12-01 09:13

Core Viewpoint - The company Zhixiang Jintai is currently conducting Phase I clinical trials for its monoclonal antibody GR2102, which targets respiratory syncytial virus (RSV) [1] Group 1 - The GR2102 injection is in the Phase I clinical trial stage [1] - Investors are inquiring about the commercialization timeline for GR2102 [1]